Amyloid accumulation and tau-induced neurofibrillary changes are associated with the development of dementia (Bloom, 2014), and cerebrospinal fluid biomarkers such as amyloid-β42 and phosphorylated tau are known to be useful in the early diagnosis of Alzheimer’s disease. The gene discussed is MAPT; the disease is dementia.